Ask AI
ProCE Banner Activity

FAQs: CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Clinical Thought

In this commentary, an expert addresses questions about the selection and sequencing of CAR T-cell therapy and bispecific antibodies in the management of patients with relapsed/refractory multiple myeloma, including approaches used in the Veterans Healthcare System.

Released: April 28, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Bristol Myers Squibb and Johnson & Johnson.

Bristol Myers Squibb

Johnson & Johnson

Target Audience

This activity is intended for hematologists, oncologists, nurses, physician associates, pharmacists, and other healthcare professionals in VA medical centers caring for patients with relapsed/refractory multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the eligibility of patients with relapsed/refractory MM for CAR T-cell therapy based on patient and disease characteristics, current indications, and expert recommendations

  • Develop individualized treatment strategies leveraging CAR T-cell or bispecific antibody therapies for patients with relapsed/refractory MM after at least 1 prior line of therapy based on clinical data, approvals, expert recommendations, and patient factors

  • Implement strategies supporting equitable access to novel therapies and clinical trials in Black and underserved populations with relapsed/refractory MM

Disclosure

Primary Author

Salyka Sengsayadeth, MD, has no relevant financial relationships to disclose.